A murine model of lung carcinoma cell lines demonstrated that KEAP1 deletion in tumours with inactivated TP53 is associated with chemoresistance through the KEAP1-NFE2L2 pathway. This evidence concerns the gene NFE2L2 and lung carcinoma.